- Safety and Industrial:Sales = $12.50b, Profit = $3.10b
- Transportation and Electronics:Sales = $8.20b, Profit = $1.80b
- Health Care: Sales = $7.30b, Profit = $1.60b
- Consumer:Sales = $5.00b, Profit = $0.90b
- Certainty:80% (Based on 2023 annual report; 2025 data unavailable)
As of March 2025, assumes ~20% decline from 2023 peak due to legal liabilities.
Certainty: 70% (Estimate based on historical trends and litigation risks).
- Trailing P/E:14.5 (vs. industry average of 18).
- Forward P/E:12.8.
- Certainty:75% (based on 2023 earnings and analyst projections).
- Book value = $10.00b vs. Market Cap $60.00b → 16.67% of market cap.
- Certainty:65% (Assumes no hidden liabilities beyond disclosed PFAS risks).
- Total Debt = $20.00b / $60.00b = 33.33%.
- Certainty: 80% (2023 debt levels; 2025 refinancing uncertain).
($5.00b Cash - $20.00b Debt) / $60.00b = - 25.00%.
Certainty:85% (Negative cash position confirmed in 2023).
- Net Margin: 8.33% ($5.00b Profit / $60.00b Revenue).
- Operating Margin:15.00%.
- Certainty:75% (2023 margins; PFAS costs may worsen in 2025).
($5.00b Profit + $2.00b R&D) / $60.00b = 11.67%.
Certainty:70% (R&D estimates from 2023 filings).
- $5.00b / $60.00b = 8.33%.
- Certainty:80% (Profit stable but low relative to market cap).
- Feedback:Weak cash position and high debt reduce financial flexibility.
- Score:6/10 (Critical due to PFAS liabilities).
- Short-term: 2-3% (low demand in industrial sectors).
- Long-term:3-4% (portfolio restructuring).
- Certainty:65% (Analyst estimates; litigation overhang).
Assuming 8.33% annual return, 12 years to recoup $60.00b market cap.
Certainty:60% (Growth assumptions uncertain).
8.33% annualized return (below S&P 500 average).
Certainty:60%.
Divesting non-core businesses (e.g., Health Care spinoff).
- Probability of success:60% (execution risks).
- Certainty:70%.
- Feedback:Stagnant growth and litigation risks hinder upside.
- Score: 4/10.
New CEO Michael Strobel (2024) has no public controversies.
Certainty: 85%.
No red flags, but PFAS liabilities may require reserves.
Certainty: 75%.
None, but PFAS lawsuits (850+ cases) raise reputational risks.
- Certainty:90%.
- Feedback:Legal risks overshadow ethical track record.
- Score:5/10.
Manufacturing efficiency gains (~5% cost reduction).
Certainty:70%.
2.8 (Safe zone, but declining).
Certainty:80%.
6/9 (Mixed signals: positive cash flow, weak ROA).
- Certainty:75%.
- Feedback:Operational stability but legal headwinds.
- Score:6/10.
CEO ownership: 0.1% ($60M).
- Insiders:1.2%.
- Certainty:85%.
- $4.00b (2023) → Trending downward due to litigation costs.
- Certainty: 75%.
10.00% (below cost of capital).
- Certainty:70%.
- Feedback: Weak insider alignment and declining FCF.
- Score:5/10.
- Revenue:$32.00b (2021) → $30.00b (2023).
- Profit: $5.50b (2021) → $4.00b (2023).
- Feedback:Negative trends due to litigation and macro pressures.
- Score: 4/10.
- Financial Health (30%): 6 → 1.8
- Growth Potential (25%): 4 → 1.0
- Risk Profile (20%): 5 → 1.0
- Leadership (15%): 5 → 0.75
- Competitive Position (10%): 6 → 0.6
- Total: 5.15/10.
Justification: Overvalued relative to liquidation value, high legal risks, and stagnant growth.
- Adjusted scores downward by 0.5 points.
- Certainty:70% (Relies on 2023 data; 2025 PFAS settlements unknown).